NCT02574858View on ClinicalTrials.gov

Study of the Safety of QRH-882260 Heptapeptide

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy Adults
Interventions
DRUG

QRH-882260

The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT02574858 - Study of the Safety of QRH-882260 Heptapeptide | Biotech Hunter | Biotech Hunter